Spotlight

An uptick in biomarker testing for non-small cell lung cancer (NSCLC) over the past decade indicates an ongoing trend toward personalization of treatment choices.

An analysis of 12 clinical trials shows no difference in mortality risk with continuous versus intermittent androgen deprivation therapy for prostate cancer.

First-line treatment that aligns with the results of biomarker testing and treatment guidelines is linked with better survival outcomes in patients with advanced or metastatic NSCLC.

Both Black and White patients with metastatic castration-sensitive prostate cancer (mCSPC) showed similar progression-free survival and overall survival in a clinical trial setting.